CAJ | 학술논문

目的总结索拉非尼在晚期肾癌患者中的疗效及药物性相关毒副反应的发生率.方法回顾性分析北京大学肿瘤医院暨北京市肿瘤防治研究所肾癌黑色素瘤内科2006年10月至2013年10月期间应用索拉非尼治疗的晚期肾癌患者的资料.统计患者的中位无进展生存时间(PFS)、总体中位总生存时间(OS)及药物不良反应发生情况.结果 174例患者服用索拉非尼,疾病控制率达92％.常规剂量400 mg,2次/d治疗的中位PFS(8.0 ±0.6)个月,疾病进展后增量至600mg 2次/d,PFS(5.0±1.0)个月,再次进展后增量至800 mg 2次/d治疗的中位PFS(2.0±0.4)个月.OS(24.0±2.8)个月.常见不良反应包括手足皮肤反应(70％)、疲乏(57.4％)、腹泻(45.2％)、皮疹(39.9％)和高血压(21.8％).结论索拉非尼治疗晚期肾癌患者疗效显著,常规剂量治疗失败后增量治疗仍能获得较长的疾病控制时间,药物安全性良好.
목적 총결색랍비니재만기신암환자중적료효급약물성상관독부반응적발생솔.방법 회고성분석북경대학종류의원기북경시종류방치연구소신암흑색소류내과2006년10월지2013년10월기간응용색랍비니치료적만기신암환자적자료.통계환자적중위무진전생존시간(PFS)、총체중위총생존시간(OS)급약물불량반응발생정황.결과 174례환자복용색랍비니,질병공제솔체92％.상규제량400 mg,2차/d치료적중위PFS(8.0 ±0.6)개월,질병진전후증량지600mg 2차/d,PFS(5.0±1.0)개월,재차진전후증량지800 mg 2차/d치료적중위PFS(2.0±0.4)개월.OS(24.0±2.8)개월.상견불량반응포괄수족피부반응(70％)、피핍(57.4％)、복사(45.2％)、피진(39.9％)화고혈압(21.8％).결론 색랍비니치료만기신암환자료효현저,상규제량치료실패후증량치료잉능획득교장적질병공제시간,약물안전성량호.
Objective To evaluate the efficacy and safety of sorafenib in Chinese patients with advanced renal cell carcinoma.Methods The data of 174 advanced renal cell carcinoma patients orally taking sorafenib in our single center from October 2006 to October 2013 was retrospectively collected.Progression free survival (PFS),overall survival (OS) of these patients and drug-related side effects were analyzed.Results Disease control rate was 92％ for the whole group.The median PFS of patients taking standard dose (400 mg bid) was (8.0 ± 0.6) months,the median PFS of patients taking increased dose (600 mg bid) after progression was (5.0 ± 1.0) months,the median PFS of patients taking increased dose (800 mg bid) after second-progression was (2.0 ± 0.4) months.The median OS was (24.0 ± 2.8) months.The common side effects included hand-foot reaction (70％),fatigue (57.4％),diarrhea (45.2％),rash (39.9％) and hypertension (21.8％).Conclusions Sorafenib has good efficacy and safety in Chinese patients with advanced renal cell carcinoma.Increased dose could bring clinical benefit after standard dose failed.